1. Marak GE, Jr, Rao NA, Antonakou Chrousos G, Sliwinski A: Experimental lens-induced granulomatous endophthalmitis in common laboratory animals. Ophthalmic Research, 1982; 14(4):292-297.
  2. Antonakou Chrousos G, Levine Ross JA, Chrousos GP, Chu FC, Kenigsberg D, Cutler GB, Jr., Loriaux DL: Ocular findings in Turner syndrome. A prospective study. Ophthalmology, 1984; 91:926-928.
  3. Antonakou Chrousos G, Parks MM, O’Neill JF: Incidence of glaucoma, retinal detachment and secondary membrane surgery in pediatric aphakic patients. Ophthalmology, 1984; 91:1238-1241.
  4. Antonakou Chrousos G, O’Neill JF, Cogan DG: Absence of the near response in a healthy adolescent. J Ped Ophthalmol and Strabismus, 1985; 22(2):76-77.
  5. Antonakou Chrousos G, Reingold DB, Chu FC, Cogan DG: Habitual head turning in spasmus nutans. An oculographic study. J Ped Ophthalmol and Strabismus,1985; 22(3):113-116.
  6. Wright K, Antonakou Chrousos G: Weill-Marchesani syndrome with bilateral angle-closure glaucoma. J Ped Ophthalmol and Strabismus, 1985; 22(4):129-132.
  7. Antonakou Chrousos G, Matsuo V, Ballen AE, Cogan DG: Near evoked nystagmus in spasmus nutans. J Ped Ophthalmol and Strabismus, 1985; 23(3):141-143.
  8. Hommer DW, Matsuo V, Wolkwitz O, Antonakou Chrousos G, Greenblatt DJ, Weingartner H, Paul SM: Benzodiazepine sensitivity in normal human subjects. Arch Gen Psychiatry, 1986; 43:542-550.
  9. Antonakou Chrousos G, Oldfield EH, Doppman JL, Cogan DG: Prevention of ocular toxicity of carmustine (BCNU) with supra-ophthalmic intracarotid infusion. Ophthalmology, 1985; 93:1471-1475.
  10. Antonakou Chrousos G, Cowdry R, Schuelein M, Abdul-Rahim A, Matsuo V, Currie JN: Downbeat nystagmus and oscillopsia associated with the use of carbamazapine (Tegretol). AM J Ophthalmol, 1987; 103:221-224.
  11. Fishbein DJ, Antonakou Chrousos G, DiChiro G, Wayner FE, Patronas WJ, Larson SM: Glucose utilization in the appropriate visual cortex with homonymous field defects. J Clin Neuro-ophthalmology, 1987; 7(2):63-68.
  12. Rabinowitz Dagi L, Antonakou Chrousos G, Cogan DG: Spasm of the near reflex associated with organic disease. Am J Ophthalmol, 1987; 103:582-585.
  13. Antonakou Chrousos G, O’Neill JF, Lueth B, Parks MM: Accommodation deficiency in young individuals. Ped Ophthalmol and Strabismus, 1988; 25 (4): 176-179.
  14. Antonakou Chrousos G, O’Neill JF, Traboulsi IE, Richmond AD, Rosenbaum K: Ocular findings in partial Trisomy 3. Ophthalmic Pediatrics and Genetics, 1988; 9 (2) 127-130.
  15. CRYO-ROP Study Group. Multicenter Trial of Cryotheraphy for Retinopathy of Prematurity. Arch Ophthalmol, 1989; 106:471-479.
  16. CRYO-ROP Study Group. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol, 1990; 108:195-204.
  17. Antonakou Chrousos G, Jaffe MJ, Schwankhasu J, Sherins RS: Eye movement disorder in Kallmann syndrome.
    Ophthalmic Pediatrics and Genetics, 1990; 11(1): 31-34
  18. Kattah JC, Zimmerman L, Antonakou Chrousos G, Kolsky MP, Chavis R: Granulomatous giant cell myositisinvolving ocular and skeletal muscles and myocardium.
    Ophthalmology, 1990; 97:520-525.
  19. Antonakou Chrousos G, Drack A, Young M, Kattah JC, Sirdofsky M: Neuroretinitis in Cat Scratch Disease. J Clin Neuro-ophthalmology, 1990; 10(2): 92-94.
  20. Holtzam AE, Chrousos GA, Kozma C, Traboulsi EI: Duane’s Retraction Syndrome III in the Fetal Alcohol Syndrome. Am J Ophthalmology, 1990; 110:565-566.
  21. Traboulsi E, Antonakou Chrousos G: Ocular findings in Turner syndrome. In: The Eye in Systemic Disease. Gold DH, Weingeist TA (Eds). JB Lippencott, Philadelphia, 1990.
  22. Antonakou Chrousos G, Traboulsi E: Kjer dominant opticatrophy. In: Birth Defects Encyclopedia, Buyse, Ml (ed), Alan R. Liss Co, New York, 1990.
  23. Antonakou Chrousos G: Duane Retraction Syndrome. In: Birth Defects Encyclopedia, Buyse, ML (ed), Alan R. Liss Co, New York, 1990.
  24. Chrousos GA, O’Neill JF: Accommodation deficiency. J Ped
    Ophthalmol and Strabismus, 1991; 27(6): 327.
  25. CRYO-ROP Study Group. Incidence and Early Course of Retinopathy of Prematurity. Ophthalmology, 1991; 98:1673-1640.
  26. Hashemi K, Traboulsi EI, Chavis RM, Scribanu N, Antonakou Chrousos G: Chorioretinal coloboma in the amniotic Band Syndrome. Ped Ophthalmol and Strabismus, 1991; 29(4): 238-239.
  27. Optic Neuritis Study Group. Chrousos GA, (Principal Investigator).
    The clinical profile of optic neuritis. Arch Ophthalmol, 1991;
    109:1673-1678.
  28. Humayun M, Kattah J, Cupps T, Limaye S, Chrousos GA.
    Papillophlebitis and arteriolar occlusion in a pregnant woman.
    J Clin Neuro-ophthalmology, 1992; 12(4):226-229.
  29. Beck R, Chrousos GA et al. Optic Neuritis Treatment Trial Results. New England J Medicine, 1992; 326(9): 581-588.
  30. Chrousos GA, Kattah JC, Belk RW et al. Side effects of the Glucocorticoid Treatment. Experience of the Optic Neuritis Treatment Trial. JAMA, 1992; 269(16):2110-2112.
  31. CRYO-ROP Study Group. Prognostic Factors in the Natural Course of Retinopathy of Prematurity. Ophthalmology, 1992;
    100:230-237.
  32. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Fellow eye abnormalities in acute unilateral optic neuritis: Experience of the Optic Neuritis Treatment Trial. Ophthalmology, 1993; 1100:691-698.
  33. Optic Neuritis Study Group. Chrousos GA(Principal Investigator). Optic Neuritis Treatment Trial. One-Year Follow-up Results. Archives of Ophthalmology, 1993; 111:773-775.
  34. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Design, methods and conduct of the Optic Neuritis Treatment Trial. Controlled Clinical Trials, 1993; 14(2):123-142.
  35. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). (1993) Controlled Clinical Trials. 14(2)143-159.
  36. Chrousos GA, DiPaolo F, Kattah JC, Laws ER. Abducens palsy following trivial head injury. Am J Ophthalmol, 1993; 116(3):387-388.
  37. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Baseline visual field profile of optic neuritis. The Experience of the Optic Neuritis Treatment Trial. Archives of Ophthalmology, 1993; 111:231-234.
  38. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). The Pelli-Robson Letter Chart: Normative data for young adults. Clinical Vision Science, 1993; 8(2):207-210.
  39. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Brain MRI in acute optic neuritis. Archives of Neurology, 1993; 50:841-846.
  40. Optic Neuritis Study Group. Chrousos GA The effect of corticosteroids for acute Optic neuritis on the subsequent development of multiple sclerosis. NEJM, 1993; 329 (24): 1764-1769.
  41. Kattah J, Chrousos GA, Roberts J, Kolsky M. Metastatic prostate cancer to the optic canal. Ophthalmology, 1993; 100:1711-1715.
  42. Optic Neuritis Study Group. Chrousos GA (Principal Investigator) Recovery from severe visual loss in optic neuritis. Archives of Ophthalmology, 1993; 111:300.
  43. CRYO-ROP Study Group. Multicenter Trial of Cryotheraphy for Retinopathy of Prematurity. Arch Ophthalmol, 1993; 111:339-344.
  44. Kattah JC, Chrousos GA, Katz PA, McCaslin B, Kolsky MP. Anterior ischemic optic neuropathy in the Churg-Strauss Syndrome. Neurology, 1994; 44:2200-2202.
  45. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol, 1994; 112:946-953.
  46. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology, 1994; 101:1771-1778.
  47. Optic Neuritis Study Group. Chrousos GA (Principal Investigator). The optic neuritis treatment trial. Three year follow-up results. Arch. Ophthalmol, 1995; 113:136-37.
  48. Optic Neuritis Study Group. Chrousos GA (Principal Investigator), Remote monitoring for multicenter trials. Controlled Clinical Trials, 1996; 17:407-414.
  49. Optic Neuritis Study Group. Chrousos GA (Principal Investigator) Cerebrospinal fluid in acute optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology, 1996 46:368-372.
  50. Optic Neuritis Study Group. Chrousos GA (Principal Investigator) Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am J Ophthalmol, 1996; 121(5):547-553.
  51. Optic Neuritis Study Group. Chrousos GA (Principal Investigor). Visual symptoms after optic neuritis. J Neuro-ophthalmol, 1997; 17(1):18-28.
  52. Optic Neuritis Study Group. Chrousos GA (PI). The five year risk of multiple sclerosis after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology, 1997; 49:1404-1413.
  53. Optic Neuritis Study Group. Chrousos GA (PI). Visual function five years after optic neuritis. Arch Ophthalmol, 1997; 115:1545-52.
  54. Optic Neuritis Study Group. Chrousos, GA (PI). The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis Neurology, 1998; 51:885-887.
  55. Moinfar N, Wagner DG., Chrousos GA, Cupples HP, Keys M. Pediatric varicella choroiditis. Br J Ophthalmol, 1999;
    82(9):1092-3.
  56. Kattah J, Mejico L, Chrousos G, Zimmerman L, Manz H. Pathologic findings in a steroid-responsive optic nerve infarct in giant cell arteritis. Neurology, 1999; 53:177-180.
  57. Optic Neuritis Study Group. Chrousos, GA (PI). Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. Am J Ophthalmol, 1999; 128:543-553.
  58. Optic Neuritis Study Group. Chrousos, GA (PI). The National Eye Institute visual function questionnaire: Experience of the ONTT. Invest. Ophthalmol Vis Sci, 2000; 41:1017-1021.
  59. Speicher MA, Goldman MH, Chrousos GA. Amiodarone optic neruopathy without disc edema. J Neuro-ophthalmol, 2000; 20(3):171-172.
  60. Optic Neuritis Study Group. Chrousos,GA(PI). The National Eye Institute visual function questionnaire. Experience of the ONTT. Invest. Ophthalmol Vis Sci, 2000; 41:1017-1021.
  61. Optic Neuritis Study Group. Chrousos, GA(PI). Interaction between HLA-DRZ and abnormal brain MRI in optic neuritis and early MS. Neurology, 2000; 54:1859-1861.
  62. Beck RW, Trobe JD, Chrousos GA et al. High and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003; 121 (7) : 944-9.
  63. Beck RW, Gal RL, Chrousos G A et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004; 137 (1) : 77-83.
  64. Beck RW, Chrousos GA (PI) et al. Neurology.Impairment 10 Years After Optic Neuritis. Archives of Neurology 2004; 61:1386-9.
  65. Chrousos GA (PI). Long – term brain MRI changes after optic neuritis in patients without cliniclly definite multiple sclerosis. Archives of Neurology 2004; 61: 1538-41.
  66. Γ. Χρούσου. Λανθασμένες διαγνωστικές εκτιμήσεις στην παιδο-οφθαλμολογία και οι συνέπειες του λάθους για το παιδί. Οφθαλμολογικά Χρονικά 2005; 15 (42) : 252-254.
  67. Ψώνη Σ., Ψύχου Φ., Χρούσου Γ. et al. Σύνδρομο Stickler. Φαινοτυπική και γονοτυπική ετερογένεια σε δύο οικογένειες. Δελτίο Α΄ Παιδιατρικής Κλινικής Πανεπιστημίου Αθηνών 2007, 54 (1) : 68-74.
  68. Optic Neuritis Study Group, Chrousos, GA (PI). Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment .Ophthalmology 2008 Jun: 115(6): 1079-1082.
  69. Kamakaris, Koutsodontis G, Tsilimbaris M, Fitsios A, Chrousos G. First report of OPA1 screening in Greek patients with autosomal dominant optic atrophy and identification of a previously underscribed OPA1 mutation. Mol Vis. 2014 May 27; 20: 691-703
  70. Yi Shiau No , Lax NZ, Chrousos G et al. MT-ND5 mutation exhibits highly variable neurological manifestations at low mutant load. EBioMedicine 2018 Apr; 30:86-93